Novan Inc
F:6LUA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Novan Inc
Other Current Liabilities
Novan Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Novan Inc
F:6LUA
|
Other Current Liabilities
$3.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$1.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$24.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
20%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$14.7B
|
CAGR 3-Years
76%
|
CAGR 5-Years
34%
|
CAGR 10-Years
15%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Other Current Liabilities?
Other Current Liabilities
3.6m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Other Current Liabilities amounts to 3.6m USD.
What is Novan Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
6%
Over the last year, the Other Current Liabilities growth was -10%. The average annual Other Current Liabilities growth rates for Novan Inc have been -22% over the past three years , 6% over the past five years .